SCHEMBL6324550

SCHEMBL6324550

O=C(O)Cc1cccc(-c2cccc3c2CC(=O)N3)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
ABL1 P00519 1/20 0.46
PLA2G10 O15496 1/20 0.43
PLA2G2A P14555 1/20 0.43
SELL P14151 3/20 0.42
SELP P16109 3/20 0.42
SELE P16581 2/20 0.42
DRD2 P14416 2/20 0.42
DRD4 P21917 2/20 0.42
DRD3 P35462 2/20 0.42
PIP4K2A P48426 1/20 0.42
PIP4K2B P78356 1/20 0.42
PTGS2 P35354 1/20 0.41
OPRM1 P35372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320660 0.85 ABL1 (0.45) ABL1DRD2DRD4DRD3PIP4K2A
SCHEMBL6321749 0.85 ABL1 (0.43) ABL1DRD2DRD4DRD3PIP4K2A
SCHEMBL6328678 0.83 ABL1 (0.44) ABL1DRD2DRD4DRD3PIP4K2A
SCHEMBL6320773 0.80 TDP2 (0.55) ABL1PIP4K2APIP4K2BBRD4CREBBP
SCHEMBL6328529 0.79 BRD4 (0.54) ABL1PIP4K2APIP4K2BBRD4CREBBP
SCHEMBL5843496 0.79 JAK2 (0.51) ABL1DRD2DRD4DRD3PIP4K2A
SCHEMBL6319668 0.78 HTR7 (0.53) ABL1DRD2DRD4DRD3PIP4K2A
SCHEMBL16090379 0.76 BRD4 (0.52) ABL1DRD2DRD4DRD3PIP4K2A
SCHEMBL17187933 0.75 PLA2G10 (0.60) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL155873 0.75 GSK3B (0.50) ABL1PIP4K2APIP4K2BOPRM1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 GRIN2D 1516/4885GRIN3B 1369/4885GRIN1 1042/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 GRIN2D 1516/4885GRIN3B 1369/4885GRIN1 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.